Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)

DSpace/Manakin Repository

Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF)
 
MEMS-HF Investigators
(2020) European Journal of Heart Failure, volume 22, issue 10, pp. 1891 - 1901
(Article)
Abstract
Aims: Heart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP)-guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: CardioMEMS™ HF system, Depression, Haemodynamic monitoring, Health-related quality of life, Heart failure, Morbidity, Cardiology and Cardiovascular Medicine, Journal Article
DOI: https://doi.org/10.1002/ejhf.1943
ISSN: 1388-9842
Publisher: Oxford University Press
Note: Funding Information: This work was supported by Abbott, Sylmar, CA, USA. Funding Information: C.E.A., S.D.A., B.A., J.B., G.E., F.K., S.R., and M.B. served on the MEMS‐HF steering committee. F.W.A. and J.J.B. were on the steering committee of the Abbott‐sponsored MONITOR‐HF study. P.B.A., M.E.B., and G.G. are employees and shareholders of Abbott. C.E.A. is also/has been a member of steering committees for trials sponsored by Boehringer Ingelheim, Novartis, ResMed, Vifor and the CTSU Oxford, and reports honoraria for consultancy and speaker fees from Abbott, Boehringer Ingelheim, Medtronic, Novartis, ResMed, Servier and Vifor; S.D.A. reports receiving fees from Abbott Vascular, Actimed, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Servier, and Vifor Pharma, and grant support from Abbott Vascular and Vifor Pharma; B.A. reports honoraria for consultancy and an unrestricted research grant from St Jude Medical, and speaker fees from Novartis, St Jude Medical and Vifor. M.B. reports honoraria for consultancy and speaker fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Cytogenetics, Medtronic, Servier and Vifor. J.B. reports honoraria for consultancy and speakers fees and scientific support by Abbott, Medtronic and Biotronik. G.E. reports honoraria for consultancy and speakers fees from Bayer, Boehringer Ingelheim, St Jude Medical, Novartis, Servier, and Vifor. F.K. reports research funding by the German Federal Ministry of Economics and Technology, the European Commission, and the German Federal Ministry of Education and Research. S.R. reports honoraria for consultancy, speaker fees and scientific support by Abbott; and has received remuneration for lectures and/or consultancy from Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Vifor and United Therapeutics, and his institution has received research grants from Actelion, Bayer, Novartis, and United Therapeutics. C.T. reports honoraria for consultancy and speakers fees from Abbott, and Novartis. L.H. and Q.Z. report no conflicts of interest. Conflict of interest: Funding Information: This work was supported by Abbott, Sylmar, CA, USA. Conflict of interest: C.E.A., S.D.A., B.A., J.B., G.E., F.K., S.R., and M.B. served on the MEMS-HF steering committee. F.W.A. and J.J.B. were on the steering committee of the Abbott-sponsored MONITOR-HF study. P.B.A., M.E.B., and G.G. are employees and shareholders of Abbott. C.E.A. is also/has been a member of steering committees for trials sponsored by Boehringer Ingelheim, Novartis, ResMed, Vifor and the CTSU Oxford, and reports honoraria for consultancy and speaker fees from Abbott, Boehringer Ingelheim, Medtronic, Novartis, ResMed, Servier and Vifor; S.D.A. reports receiving fees from Abbott Vascular, Actimed, Bayer, Boehringer Ingelheim, Cardiac Dimension, Impulse Dynamics, Novartis, Servier, and Vifor Pharma, and grant support from Abbott Vascular and Vifor Pharma; B.A. reports honoraria for consultancy and an unrestricted research grant from St Jude Medical, and speaker fees from Novartis, St Jude Medical and Vifor. M.B. reports honoraria for consultancy and speaker fees from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Cytogenetics, Medtronic, Servier and Vifor. J.B. reports honoraria for consultancy and speakers fees and scientific support by Abbott, Medtronic and Biotronik. G.E. reports honoraria for consultancy and speakers fees from Bayer, Boehringer Ingelheim, St Jude Medical, Novartis, Servier, and Vifor. F.K. reports research funding by the German Federal Ministry of Economics and Technology, the European Commission, and the German Federal Ministry of Education and Research. S.R. reports honoraria for consultancy, speaker fees and scientific support by Abbott; and has received remuneration for lectures and/or consultancy from Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Vifor and United Therapeutics, and his institution has received research grants from Actelion, Bayer, Novartis, and United Therapeutics. C.T. reports honoraria for consultancy and speakers fees from Abbott, and Novartis. L.H. and Q.Z. report no conflicts of interest. Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
(Peer reviewed)